...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study
【24h】

What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study

机译:宫颈筛查适用于针对高风险HPV接种疫苗的女性? 模拟研究

获取原文
获取原文并翻译 | 示例

摘要

Women vaccinated against HPV16/18 are approaching the age for cervical screening; however, an updated screening algorithm has not been agreed. We use a microsimulation model calibrated to real published data to determine the appropriate screening intensity for vaccinated women. Natural histories in the absence of vaccination were simulated for 300,000 women using 10,000 sets of transition probabilities. Vaccination with ( i ) 100% efficacy against HPV16/18, ( ii ) 15% cross‐protection, ( iii ) 22% cross‐protection, ( iv ) waning vaccine efficacy and ( v ) 100% efficacy against HPV16/18/31/33/45/52/58 was added, as were a range of screening scenarios appropriate to the UK. To benchmark cost‐benefits of screening for vaccinated women, we evaluated the proportion of cancers prevented per additional screen (incremental benefit) of current cytology and likely HPV screening scenarios in unvaccinated women. Slightly more cancers are prevented through vaccination with no screening (70.3%, 95% CR: 65.1–75.5) than realistic compliance to the current UK screening programme in the absence of vaccination (64.3%, 95% CR: 61.3–66.8). In unvaccinated women, when switching to HPV primary testing, there is no loss in effectiveness when doubling the screening interval. Benchmarking supports screening scenarios with incremental benefits of ≥2.0%, and rejects scenarios with incremental benefits ≤0.9%. In HPV16/18‐vaccinated women, the incremental benefit of offering a third lifetime screen was at most 3.3% (95% CR: 2.2–4.5), with an incremental benefit of 1.3% (?0.3–2.8) for a fourth screen. For HPV16/18/31/33/45/52/58‐vaccinated women, two lifetime screens are supported. It is important to know women's vaccination status; in these simulations, HPV16/18‐vaccinated women require three lifetime screens, HPV16/18/31/33/45/52/58‐vaccinated women require two lifetime screens, yet unvaccinated women require seven lifetime screens.
机译:针对HPV16 / 18接种疫苗的妇女正在接近宫颈筛查的年龄;但是,未达成更新的筛选算法。我们使用校准到真实公布数据的微仿模型,以确定接种疫苗的妇女的适当筛选强度。在没有接种疫苗的情况下,使用10,000套过渡概率模拟了在没有疫苗接种的自然历史。用(I)对HPV16 / 18的100%疗效,(ii)15%的交叉保护,(iii)22%的交叉保护,(iv)疫苗疗效和(v)免受HPV16 / 18/31的疗效100%的疗效/ 33/45 / 52/58加入,与适合英国的筛查情景一样。为了对疫苗接种的女性进行筛选的成本效益,我们评估了当前细胞学的额外筛选(增量效益)的癌症的比例,并且可能在未接触的女性中的HPV筛查情景。通过没有筛选(70.3%,95%Cr:65.1-75.5),通过疫苗接种来预防更多的癌症比在没有疫苗接种的情况下对当前英国筛查计划的实际遵守(64.3%,95%Cr:61.3-66.8)。在未接触的女性中,在切换到HPV的主要测试时,在加倍筛选间隔时没有有效的损失。基准测试支持筛选方案,增量效益≥2.0%,并拒绝具有增量效益的方案≤0.9%。在HPV16 / 18疫苗的女性中,提供第三终身筛选的增量益处至多3.3%(95%Cr:2.2-4.5),第四个屏幕的增量益处为1.3%(?0.3-2.8)。对于HPV16 / 18/31/33/45 / 52/58/58疫苗的妇女,支持两种终身屏幕。了解女性的疫苗接种状态非常重要;在这些模拟中,HPV16 / 18疫苗的女性需要三个终身屏幕,HPV16 / 18/31/33/45 / 52/58接种疫苗的妇女需要两个终身屏幕,但未接触的妇女需要七个终身屏幕。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号